growth innov focu
share continu benefit manag
abil consist execut enhanc compani
pipelin call management emphas lilli strong
growth prospect discuss pipelin candid
newsflow ahead includ covid therapeut alzheim
growth prospect remain robust volum growth offset price pressur
yield unchang revenu growth prospect bump ep
annual continu forecast compound-annual-growth-rate revenue oper
incom ep
although discuss call next pipelin event high-dos
trulic result mid-lat may plan compar data cross-trial novo
ozemp expect trulic data disclos endo
abstract public mid-lat may plu addit data virtual ada
meet june recal june lilli announc trulic
mg show superior lower weight reduct vs trulic mg
week lilli character safeti toler profil higher
dose consist known profil trulic mg ozemp
current view efficaci trulic approv dose
week trulic mg monotherapi lower baselin placebo
weight kg week ozemp mg monotherapi lower
baselin placebo-adjust weight kg kg placebo-adjust
expect fda approv high-dos trulic late novo cover mark
despit smallest us major pharma lilli move three covid
treatment candid forward make stand among major pharma
compani manag highlight develop three covid
therapeut candid baricitinib jak potenti
antibodi therapi abcellera collabor exhibit
baricitinib jak part niaid sponsor adapt phase
treatment trial actt includ remdesivir experiment arm
initi result baricitinib result expect june manag
state believ baricitinib could potenti dampen
cytokin storm occur hospit patient
fight combat inflamm lung often lead
requir ventil cso skovronski ad adapt
major pharmaceut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
trial niaid hospit patient rather later
diseas progress design trial primarili look
effect baricitinib inflammatori cascad notabl
trial current conceiv factori design remdesivir
cours addit look clinic outcom patient
viral load factor also evalu scaling-
comment small molecul produc larg
capac alreadi approv geographi around world
rheumatoid arthriti depend qualiti data
benefit/risk see patient could expect could
potenti move quickli success
mab studi ph trial hospit
patient pneumonia presum confirm
trial estim enrol particip primari endpoint
number ventil free day result expect june cso
skovronski said level plasma strongli correl
ard risk sever base multipl studi human trial
test whether inhibit effect monoclon antibodi
reduc progress ard need mechan
antibodi therapi collabor abcellera current
assess pre-clin studi cso skovronski state third
potenti signific program part previous announc
collabor abcellera pursu antibodi therapi
potenti treatment prevent think
see rel high probabl technic success given success
neutral antibodi virus also given
seen preclin project also one
imagin broad treatment paradigm antibodi like like
work sick patient could potenti prophylact use
sort demand larg quantiti plan submit ind
end may allow start clinic trial
investor call includ comment three alzheim candid biogen
aducanumab file delay effect share week investor
continu see option lilli alzheim portfolio head
skovronski respond question donanemab antibodi trial
trailblazer-alz earli symptomat alzheim state realli
robust plaque-clear antibodi know clear plaqu quit great
extent quit quickli well phase ii studi design
demonstr efficaci rel larg homogen popul
alzheim patient lilli expect result earli brought tau
antibodi candid zagotenemab mevidalen dementia state
similarli tau antibodi well symptomat pam phase ii
studi design efficaci similarli fulli enrol move along
previous commun time line chang alzheim portfolio
clinicaltri gov indic zagotenemab ph earli symptomat alzheim
primari complet aug ph presenc lewi bodi
dementia primary/studi complet juli
line result potenti percept driver lilli tau
candid prospect trial investig three differ dosag
semorinemab vs placebo patient prodrom mild alzheim diseas
trial primari efficaci endpoint cdr-sb primari complet jun
accord roch earn present compani project
regulatori submiss semorinemab beyond time-frame
roch cover mark purcel
base case ep premium peer averag due lilli better
growth prospect ep compound-annual-growth-rate vs group average lower exposur patent
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
earn forecast alzheim
newsow surpris upsid
growth driver upsid yield ep
forecast alzheim surpris
upsid investor enthusiasm
impact nancial result immateri
solid growth prospect balanc high
growth low doubl digit long-term ep
growth anticip margin expans
expect posit newsow tirzepatid ph
diabet candid rule
side effect risk sinc drug includ
novel mechan gip alzheim
equal-weight share see
compani robust prospectsbalanc
ep note risk
modest covid-rel impact growth
pipelin newsow diabet
transact enhanc long-term growth
consensu
view descript risk reward theme
financi key pipelin agent
competit pressur covid-rel
factor drive earn
impact wors expect
aducanumab -amyloid antibodi ling decis
fda
trulic high-dos data ada june
virtual posit top-line
quarterli result nancial guidanc updat
jardianc taltz verzenio
alzheim
china india
view explan region hierarchi
research highest favor quintil
upsid risk nancial result
tirzepatid diabet alzheim s-relat
newsow compet product disappoint
tirzepatid alzheim compet drug
surpris upsid new litig risk
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
exhibit new vs old consensu estim
price
price
price
valuat methodolog risk associ price target rate recommend referenc research report pleas contact client support follow us/canada hong kong
latin america london singapor sydney tokyo altern may contact invest repres
morgan stanley research broadway attent research manag new york ny usa
price data
price data
